0 likes | 0 Vues
As the EU strengthens its autonomy in bio-based manufacturing and scales-up infrastructure, this might be the moment for pharma and biotech companies to collaborate, lead, and contribute to a better future of this industry. A strategic shift is inevitable, however, under expert counsel it could turn the biggest challenges into opportunities.
E N D